Heron Therapeutics, Inc. engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy.
Market Cap | 179.521 Million | Shares Outstanding | 118.888 Million | Avg 30-day Volume | 2.063 Million |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.38 |
Price to Revenue | 4.7968 | Debt to Equity | 6.9214 | EBITDA | -214.638 Million |
Price to Book Value | 21.0032 | Operating Margin | -211.4365 | Enterprise Value | 505.161 Million |
Current Ratio | 2.384 | EPS Growth | 0.126 | Quick Ratio | 1.746 |
1 Yr BETA | 1.8458 | 52-week High/Low | 6.38 / 1.48 | Profit Margin | -220.5526 |
Operating Cash Flow Growth | 26.591 | Altman Z-Score | -9.7134 | Free Cash Flow to Firm | -136.522 Million |
Earnings Report | 2023-05-08 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
37,879 | 2023-02-22 | 1 | |
|
577,879 | 2023-02-22 | 1 | |
|
4,537,879 | 2023-02-22 | 2 | |
|
4,500,000 | 2023-01-30 | 2 | |
|
11,750,000 | 2023-01-30 | 1 | |
MANHARD KIMBERLY EVP, DRUG DEVELOPMENT |
|
149,365 | 2023-01-18 | 7 |
POYHONEN JOHN PRESIDENT & CCO |
|
66,385 | 2023-01-18 | 6 |
QUART BARRY D CHIEF EXECUTIVE OFFICER |
|
850,000 | 2023-01-18 | 5 |
SZEKERES DAVID LESLIE EVP, CHIEF OPERATING OFFICER |
|
49,788 | 2023-01-18 | 6 |
PERAZA LISA VP, CHIEF ACCOUNTING OFFICER |
|
42,631 | 2023-01-18 | 6 |
|
129,192 | 2022-12-16 | 1 | |
|
129,032 | 2022-12-16 | 1 | |
|
129,392 | 2022-12-16 | 1 | |
|
132,442 | 2022-12-16 | 1 | |
|
132,442 | 2022-12-16 | 1 | |
|
No longer subject to file | 2020-12-31 | 0 | |
HOFFMAN ROBERT CFO & SVP, FINANCE |
|
0 | 2019-12-19 | 0 |
ROSEN ROBERT PRESIDENT |
|
0 | 2018-12-15 | 0 |
|
5,851,503 | 2018-09-12 | 0 | |
DRAZBA BRIAN G. VP, FINANCE & CFO |
|
3,798 | 2016-04-29 | 0 |
MARSHALL PAUL SVP, TECHNICAL OPERATIONS |
|
2,200 | 2016-03-21 | 0 |
CLENDENINN NEIL JAMES SVP & CHIEF MEDICAL OFFICER |
|
0 | 2015-10-12 | 0 |
|
No longer subject to file | 2014-12-31 | 0 | |
|
No longer subject to file | 2014-12-31 | 0 | |
GELDER MARK S. MD SVP & CHIEF MEDICAL OFFICER |
|
0 | 2014-12-12 | 0 |
WHELAN JOHN CFO |
|
254,088 | 2013-07-18 | 0 |
ADAM MICHAEL A CHIEF OPERATING OFFICER |
|
0 | 2013-02-08 | 0 |
|
0 | 2013-01-01 | 0 | |
|
0 | 2012-05-29 | 0 | |
|
0 | 2012-05-29 | 0 | |
BARR JOHN VICE PRESIDENT OF R&D |
|
0 | 2011-07-08 | 0 |
|
No longer subject to file | 2011-07-01 | 0 | |
|
No longer subject to file | 2011-07-01 | 0 | |
|
No longer subject to file | 2011-07-01 | 0 | |
|
No longer subject to file | 2011-07-01 | 0 | |
|
No longer subject to file | 2011-07-01 | 0 | |
|
26,666,667 | 2011-07-01 | 0 | |
|
202,072 | 2010-05-20 | 0 | |
|
210,234 | 2010-05-20 | 0 | |
PRENTKI RONALD J PRESIDENT & CEO |
|
0 | 2010-02-17 | 0 |
|
15,000 | 2008-05-28 | 0 | |
|
71,900 | 2008-02-28 | 0 | |
WHITEFORD STEPHEN V.P., FINANCE & CFO |
|
15,000 | 2006-12-15 | 0 |
DRURY STEPHEN A |
|
83,283 | 2006-08-11 | 0 |
|
69,544 | 2006-08-11 | 0 | |
OCONNELL MICHAEL CHIEF EXECUTIVE OFFICER |
|
45,000 | 2006-01-10 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-02-24 19:20:31 -0500 | 2023-02-22 | A | 37,879 | a | 37,879 | direct | 2.1552 | -0.431 | 3.0172 | 5 | -0.431 | 6 | ||||
2023-02-24 19:20:31 -0500 | 2023-02-22 | A | 227,272 | a | 227,272 | direct |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
HERON THERAPEUTICS INC HRTX | 2023-03-31 22:15:04 UTC | 4.3898 | 0.4302 | 1400000 |
HERON THERAPEUTICS INC HRTX | 2023-03-31 21:45:05 UTC | 4.3898 | 0.4302 | 1400000 |
HERON THERAPEUTICS INC HRTX | 2023-03-31 21:15:03 UTC | 4.3654 | 0.4546 | 1400000 |
HERON THERAPEUTICS INC HRTX | 2023-03-31 20:45:04 UTC | 4.3654 | 0.4546 | 1400000 |
HERON THERAPEUTICS INC HRTX | 2023-03-31 20:15:04 UTC | 4.3654 | 0.4546 | 1400000 |
HERON THERAPEUTICS INC HRTX | 2023-03-31 19:45:04 UTC | 4.3654 | 0.4546 | 1400000 |
HERON THERAPEUTICS INC HRTX | 2023-03-31 19:15:04 UTC | 4.3654 | 0.4546 | 1400000 |
HERON THERAPEUTICS INC HRTX | 2023-03-31 18:45:04 UTC | 4.3654 | 0.4546 | 1400000 |
HERON THERAPEUTICS INC HRTX | 2023-03-31 18:15:04 UTC | 4.3654 | 0.4546 | 1400000 |
HERON THERAPEUTICS INC HRTX | 2023-03-31 17:45:04 UTC | 4.3654 | 0.4546 | 1400000 |
HERON THERAPEUTICS INC HRTX | 2023-03-31 17:15:03 UTC | 4.3654 | 0.4546 | 1400000 |
HERON THERAPEUTICS INC HRTX | 2023-03-31 16:45:04 UTC | 4.3715 | 0.4485 | 1400000 |
HERON THERAPEUTICS INC HRTX | 2023-03-31 16:15:04 UTC | 4.3715 | 0.4485 | 1400000 |
HERON THERAPEUTICS INC HRTX | 2023-03-31 15:45:04 UTC | 4.3715 | 0.4485 | 1400000 |
HERON THERAPEUTICS INC HRTX | 2023-03-31 15:15:03 UTC | 4.3715 | 0.4485 | 1400000 |
HERON THERAPEUTICS INC HRTX | 2023-03-31 14:45:04 UTC | 4.3715 | 0.4485 | 1400000 |
HERON THERAPEUTICS INC HRTX | 2023-03-31 14:15:04 UTC | 4.3715 | 0.4485 | 1400000 |
HERON THERAPEUTICS INC HRTX | 2023-03-31 13:45:03 UTC | 4.4009 | 0.4191 | 1400000 |
HERON THERAPEUTICS INC HRTX | 2023-03-31 13:15:03 UTC | 4.4009 | 0.4191 | 1000000 |
HERON THERAPEUTICS INC HRTX | 2023-03-31 12:45:03 UTC | 4.4009 | 0.4191 | 1000000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
Prudential Investment Portfolios 12- PGIM QMA Long-Short Equity Fund | HRTX | -3500.0 shares, $-37415.0 | 2021-09-30 | N-PORT |
Advanced Series Trust- AST QMA U.S. Equity Alpha Portfolio | HRTX | -47100.0 shares, $-503499.0 | 2021-09-30 | N-PORT |
Federated Hermes Adviser Series- Federated Hermes MDT Market Neutral Fund | HRTX | -21601.0 shares, $-54002.5 | 2022-12-31 | N-PORT |
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund | HRTX | -9500.0 shares, $-23750.0 | 2022-12-31 | N-PORT |